Max Miranda, MD
Gastroenterology · Duluth, MNNPI 1225259567
Payments from drug & device makers
Across 12 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$84
- Boston Scientific$62
- E.r. Squibb & Sons, L.L.C.$43
- Ferring Pharmaceuticals Inc.$27
- QOL Medical, LLC$22
- Aimmune Therapeutics, Inc.$19
- plus $12 from 1 others
What the payments were for
- Food & beverage$270100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 4 | $84 |
| Boston Scientific | 1 | $62 |
| E.r. Squibb & Sons, L.L.C. | 1 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $27 |
| QOL Medical, LLC | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 2 | $12 |
How this compares
$270 in reported general payments places this provider in the 50th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $589,715 |
| CreonLipase/Protease/Amylase | 24 | $72,746 |
| XifaxanRifaximin | 20 | $66,980 |
| Dexlansoprazole DrDexlansoprazole | 146 | $50,310 |
| LinzessLinaclotide | 40 | $39,073 |
| Pantoprazole Sodium | 811 | $12,553 |
| Sucralfate | 147 | $7,492 |
| Lansoprazole | 132 | $5,698 |
| Colestipol Hcl | 30 | $4,122 |
| Omeprazole | 89 | $2,344 |
| Rabeprazole Sodium | 45 | $2,145 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 76 | $1,989 |
| Esomeprazole Magnesium | 51 | $1,041 |
| Spironolactone | 25 | $698 |
| Famotidine | 54 | $678 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Duluth
- Edward LoftusRochester$5.2M
- Andres AcostaRochester$2.8M
- Madhusudan GroverRochester$2.5M
- Naresh GunaratnamEagan$2.1M
- Michael CamilleriRochester$1.9M
- Vinay ChandrasekharaRochester$1.8M
- Joseph MurrayRochester$1.2M
- Sahil KhannaRochester$1.2M
- Alina AllenRochester$986K
- John KisielRochester$856K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.